Publications by authors named "Dimitri Semizarov"

Claim this Profile
A
A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
Josep M Llibre, Christoph Boesecke, Juhi Moon, Patrick M Lank, Michael G Miller, Dimitri Semizarov

J Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
Stanislas Pol, Alexander J Thompson, Michelle Collins, Elisa Venier, Laurent Cotte, Dimitri G Semizarov

Hepatology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.
Markus Cornberg, Dietrich Hüppe, Christoph Sarrazin, Adriana Ahumada, Francisco Jorquera Plaza, Dimitri Semizarov

Adv Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Drug-Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations.
Dwaipayan Mukherjee, Michelle Collins, Douglas E Dylla, Jatinder Kaur, Dimitri Semizarov

Infect Dis Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial.
Christopher J Byrne, Andrew Radley, Sarah K Inglis, Lewis Beer, Nicki Palmer, Dimitri Semizarov

Aliment Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
Steven Flamm, K Rajender Reddy, Neddie Zadeikis, Tarek Hassanein, Bruce R Bacon, Dimitri Semizarov

Clin Gastroenterol Hepatol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax).
Lloyd T Lam, Xin Lu, Haichao Zhang, Rick Lesniewski, Saul Rosenberg, Dimitri Semizarov

Mol Cancer Ther· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.
Xin Lu, Ke Zhang, Charles Van Sant, John Coon, Dimitri Semizarov

BMC Med Genomics· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Xuesong Liu, Edward K Han, Mark Anderson, Yan Shi, Dimitri Semizarov

Mol Cancer Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.
Edward T Olejniczak, Charles Van Sant, Mark G Anderson, Gang Wang, Stephen K Tahir, Dimitri Semizarov

Mol Cancer Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway.
Charles Van Sant, Gang Wang, Mark G Anderson, Oscar J Trask, Rick Lesniewski, Dimitri Semizarov

Mol Cancer Ther· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.
Leiming Li, Xiaoyu Lin, Michael Staver, Alexander Shoemaker, Dimitri Semizarov

Cancer Res· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
Zhan Xiao, John Xue, Dimitri Semizarov, Thomas J Sowin, Saul H Rosenberg

Int J Cancer· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
siRNA-mediated gene silencing: a global genome view.
Dimitri Semizarov, Paul Kroeger, Stephen Fesik

Nucleic Acids Res· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specificity of short interfering RNA determined through gene expression signatures.
Dimitri Semizarov, Leigh Frost, Aparna Sarthy, Paul Kroeger, Donald N Halbert

Proc Natl Acad Sci U S A· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis